Kaplan, NecatiYılmaz, İbrahimKaraarslan, NumanKaya, Yasin EmreŞirin, Duygu YaşarÖzbek, Hanefi2022-05-112022-05-1120191389-20101873-4316https://doi.org/10.2174/1389201020666190506124548https://hdl.handle.net/20.500.11776/5463Background: The study aimed to investigate the effects of the active ingredient, nimodipine, on chondrocyte proliferation and extracellular matrix (ECM) structures in cartilage tissue cells. Methods: Chondrocyte cultures were prepared from tissues resected via surgical operations. Nimodipine was then applied to these cultures and molecular analysis was performed. The data obtained were statistically calculated. Results: Both, the results of the (3-(4,5 dimethylthiazol2-yl)-2,5-diphenyltetrazolium (MTT) assay and the fluorescence microscope analysis [a membrane permeability test carried out with acridine orange/propidium iodide staining (AO/PI)] confirmed that the active ingredient, nimodipine, negatively affects the cell cultures. Conclusion: Nimodipine was reported to suppress cellular proliferation; chondroadherin (CHAD) and hypoxia-inducible factor-1 alpha (HIF-1 alpha) expression thus decreased by 2.4 and 1.7 times, respectively, at 24 hrs when compared to the control group (p < 0.05). Furthermore, type II collagen (COL2A1) expression was not detected (p < 0.05). The risk that a drug prescribed by a clinician in an innocuous manner to treat a patient by relieving the symptoms of a disease may affect the proliferation, differentiation, and viability of other cells and/or tissues at the molecular level, beyond its known side effects or adverse events, should not be forgotten.en10.2174/1389201020666190506124548info:eu-repo/semantics/openAccessChondroadherinchondrocytehypoxia-inducible factor-1 alphanimodipinetype II collagenmatrix structuresArticle206517524Q3WOS:0005768275000022-s2.0-8507100466931057106Q2